ONCO
Onconetix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.66
−1.25%Sep 14, 2026, 15:03 UTC
Onconetix, Inc. agreed to lend Realbotix, LLC up to $5.0 million under an unsecured grid promissory note, with $2.5 million advanced initially, maturing September 11, 2027.
Sep 14, 2026, 11:30 UTC
Realbotix LLC, a wholly owned subsidiary of Realbotix Corp., entered into an unsecured bridge loan facility with Onconetix, Inc. in connection with their proposed merger.
Sep 3, 2026, 12:30 UTC
Onconetix entered into a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.
Source:Aug 6, 2026, 12:30 UTC
Realbotix, the acquisition target of Onconetix, secured an agreement with a streaming platform to feature its humanoid robot in an upcoming episode of an Emmy-winning series.
Source:Jul 29, 2026, 00:00 UTC
Onconetix, Inc. entered into a committed equity facility agreement allowing it to sell up to $750 million of its common stock over time at prevailing market prices.
Jul 29, 2026, 00:00 UTC
Onconetix, Inc. signed a securities purchase agreement for a $30,249,600 Series F PIPE financing, issuing 37,812 shares of Series F convertible preferred stock at $1,000 per share.